6533b86ffe1ef96bd12ce98e

RESEARCH PRODUCT

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their High-Affinity State

Vladimir ShalgunovP. Michel FransenHenk M. JanssenJan-peter Van WieringenAnton G.m. JanssenMartin C. MichelJan BooijPhilip H. Elsinga

subject

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drug

description

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived [ 18F] or [123I]. Binding experiments showed that several AMC compounds have a high affinity and selectivity for D2/3R and act as agonists. Two fluorine-containing compounds were [18F]-labeled, and both displayed specific binding to striatal D2/3R in rat brain slices in vitro. These findings encourage further in vivo evaluations.

10.1021/jm401384whttps://research.rug.nl/en/publications/ac1dee1c-ec5a-4268-b2f5-a70f743b8ee2